Joint-Predominant Rheumatic Complications of Immune Checkpoint InhibitorTherapy in Patients with Thymic Epithelial Tumors

Cristina Mullenix, Madison Ballman, Haobin Chen, Shannon Swift, Meredith J. McAdams, Yo Ting Tsai, Renee N. Donahue, Trina Poretta, Sarthak Gupta, Patrick J. Loehrer, Jeffrey Schlom, James L. Gulley, Arun Rajan

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers. However, activation of the immune system can occasionally cause life-threatening toxicity involving critical organs. Induction of immune-mediated toxicity is a significant concern for patients with thymic epithelial tumors (TETs) due to defects in immune tolerance. An increased risk of skeletal and cardiac muscle inflammation following treatment with ICIs is well recognized in patients with advanced TETs. However, uncommon musculoskeletal and rheumatic complications can also occur. The cases presented in this report highlight the spectrum of presentation of immune-mediated, joint-predominant musculoskeletal adverse events in patients with advanced TETs treated with ICIs, including polymyalgia rheumatica-like illness and inflammatory arthritis.

Original languageEnglish
Pages (from-to)E353-E356
JournalOncologist
Volume27
Issue number4
DOIs
StatePublished - Apr 2022

Keywords

  • immunotherapy
  • inflammatory arthritis
  • myositis
  • polymyalgia rheumatica
  • thymic epithelial tumors

Fingerprint

Dive into the research topics of 'Joint-Predominant Rheumatic Complications of Immune Checkpoint InhibitorTherapy in Patients with Thymic Epithelial Tumors'. Together they form a unique fingerprint.

Cite this